Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again' - 2How to watch the 2025 Macy's Thanksgiving Day Parade for free
- 3Why doing good also makes us feel good, during the holidays and beyond
- 4Exploring School Life: Self-awareness and Illustrations
- 5Danish warship sunk by famed British admiral discovered after 225 years
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- The year's first meteor shower and supermoon clash in January skies
- UK consumer confidence plunges amid escalating Iran conflict
- Delta flight bound for Atlanta makes emergency landing after engine issue
- NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- Bother Control Administrations for 2024: Decide for Your Home
- Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- 1,000-mile Saharan dust storm, from the sky and from the ground
- Slims down for Maintainable Weight reduction
